GVK BIO steps into GLP tox with Vanta Bioscience acquisition
Vanta complies with OECD GLP, ISO, USFDA GLP (21 CFR Part 58 rev. 2009) regulatory guidelines, and offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries.
Manni Kantipudi, CEO, GVK BIO, said: “The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology.”
The company’s sole facility is GLP and AAALAC accredited and armed with high-end equipment, and has infrastructure like “Individually ventilated Cages” and “Intelligent Building Management” systems. The facility houses GLP-trained scientific personnel with experience and expertise in study design and execution of regulatory directed studies leading to IND filings.
Gerard Schwickerath, VP and General Manager, Vanta Bioscience, added: “Vanta Bioscience team is pleased that the world-class research GLP and AAALAC accredited organization will continue under the direction of GVK BIO. We are delighted to transition into an organization that can expand our offerings and provide further opportunities to our clients and staff.”
Dorothy Paul, a spokeswoman for GVK, told us: "There is a demand for GLP toxicology in India. The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology."
Prior Issues
The acquisition comes a little more than a month after the EMA announced it would open an investigation into allegations that GVK falsified electrocardiograms in eight clinical trials.
GVK had until early October to respond to EMA requests on the root cause of the issues affecting the Hyderabad, India site.
